Impact of a Multifaceted Intervention on Prescribing of Proton Pump Inhibitors for Stress Ulcer Prophylaxis in the Critically Ill
Archives of Critical Care Medicine,
Vol. 1 No. 2 (2015),
28 October 2023
Abstract
Background: Lack of well-supported evidence clearly defining one agent as superior to the other for use in stress ulcer prophylaxis (SUP) has led to an array of treatment strategies. Studies comparing histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) have shown H2RAs to be non-inferior to PPIs at preventing clinically significant gastric bleeding. This, in addition to the decreased cost associated with H2RAs, has led to the adoption of H2RAs as the preferred agent for SUP at our institution.
Objectives: To evaluate the impact of developing a guideline and removing PPIs from computerized order entry PowerPlans on PPI prescribing for SUP in critically ill patients.
Patients and Methods: Members of the critical care service developed a guideline to direct SUP and removed pantoprazole from two critical care admission PowerPlans. In this interventional study with a historical control, adult patients admitted to the medical or surgical[1]trauma ICU and prescribed a PPI were evaluated during two time periods before and after the interventions. Patients were excluded if they were receiving a PPI for a reason other than SUP. Patients were assessed daily for an indication for SUP. These included mechanical ventilation, high dose steroids, and coagulopathy.
Results: A total of 92 and 60 patients were included in the pre- and post-intervention groups, respectively. PPI use for SUP was reduced from 38% in the pre-intervention group to 15.6% in the post-intervention group (P < 0.0001). PPI days adjusted for LOS were not different between the pre- and post-intervention groups (84% vs 86%, P = 0.5909). Of the total PPI days, 52.4% (95% CI 48.8 - 56.1) were classified as inappropriate because there was no indication, while the remaining 47.6% (95% CI 43.9 - 51.2) had an indication but should have received a H2RA. The total cost associated with guideline non-adherence was $1802.
Conclusions: Our multifaceted intervention reduced the number of days in which a PPI was prescribed for SUP in the overall ICU population; however, it did not impact the duration of PPI therapy. Patients either had no indication for SUP, or had an indication where less costly H2RAs could have been used. Additional opportunity exists to improve cost-effective prescribing of SUP for critically ill patients
- Histamine H2 Antagonists
- Proton Pump Inhibitors
- Critical Illness
How to Cite
References
Subramanian R, McCashland T. Gastrointestinal hemorrhage. In:
Hall JB, Schmidt GA, Wood LH, editors. Principles of Critical Care.
New York: McGraw-Hill; 2005.
Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al.
Risk factors for gastrointestinal bleeding in critically ill patients.
Canadian Critical Care Trials Group. N Engl J Med. 1994;330(6):377–
doi: 10.1056/NEJM199402103300601. [PubMed: 8284001]
Steinberg KP. Stress-related mucosal disease in the critically ill patient: Risk factors and strategies to prevent stressrelated bleeding in the intensive care unit. Crit Care Med.
;30(Supplement):S362–4. doi: 10.1097/00003246-200206001-
[PubMed: 12072662]
Martindale RG. Contemporary strategies for the prevention of
stress-related mucosal bleeding. Am J Health Syst Pharm. 2005
;15(62):11–7.
Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton
pump inhibitors versus histamine 2 receptor antagonists for
stress ulcer prophylaxis in critically ill patients: a systematic
review and meta-analysis. Crit Care Med. 2013;41(3):693–705. doi:
1097/CCM.0b013e3182758734. [PubMed: 23318494]
Coursol CJ, Sanzari SE. Impact of stress ulcer prophylaxis algorithm study. Ann Pharmacother. 2005;39(5):810–6. doi: 10.1345/
aph.1D129. [PubMed: 15811900]
MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2
antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*. Crit Care Med. 2014;42(4):809–15. doi:
1097/CCM.0000000000000032. [PubMed: 24365863]
MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract
hemorrhage and infectious complications in the intensive care
unit. JAMA Intern Med. 2014;174(4):564–74. doi: 10.1001/jamainternmed.2013.14673. [PubMed: 24535015]
de Leon N, Sharpton S, Burg C, Gross AK, Li F, Thompson A, et al.
The Development and Implementation of a Bundled Quality Improvement Initiative to Reduce Inappropriate Stress Ulcer Prophylaxis. ICU Direct. 2013;4(6):322–5. doi: 10.1177/1944451613508185.
Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA,
et al. Why don't physicians follow clinical practice guidelines?
A framework for improvement. JAMA. 1999;282(15):1458–65.
[PubMed: 10535437]
Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis.
Am J Gastroenterol. 2012;107(4):507–20. doi: 10.1038/ajg.2011.474.
[PubMed: 22290403]
Ballard DJ, Ogola G, Fleming NS, Stauffer BD, Leonard BM, Khetan
R, et al. Impact of a standardized heart failure order set on mortality, readmission, and quality and costs of care. Int J Qual Health
Care. 2010;22(6):437–44. doi: 10.1093/intqhc/mzq051. [PubMed:
Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA. 1995;274(9):700–5.
[PubMed: 7650822
- Abstract Viewed: 36 times
- PDDF Downloaded: 0 times